Epidermal Growth Factor Receptor Is Related to Poor Survival in Glioblastomas: Single-Institution Experience.
10.3349/ymj.2013.54.1.101
- Author:
Youngmin CHOI
1
;
Young Jin SONG
;
Hyung Sik LEE
;
Won Joo HUR
;
Ki Han SUNG
;
Ki Uk KIM
;
Sun Seob CHOI
;
Su Jin KIM
;
Dae Cheol KIM
Author Information
1. Department of Radiation Oncology, Dong-A University School of Medicine, Busan, Korea.
- Publication Type:Original Article ; Research Support, Non-U.S. Gov't
- Keywords:
Epidermal growth factor receptor;
glioblastoma;
radiotherapy;
survival
- MeSH:
Adult;
Aged;
Brain Neoplasms/metabolism/*mortality/radiotherapy/surgery;
Female;
*Gene Expression Regulation, Neoplastic;
Glioblastoma/metabolism/*mortality/radiotherapy/surgery;
Humans;
Immunohistochemistry;
Male;
Middle Aged;
Proportional Hazards Models;
Radiotherapy;
Receptor, Epidermal Growth Factor/*metabolism;
Treatment Outcome
- From:Yonsei Medical Journal
2013;54(1):101-107
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: There are conflicting results surrounding the prognostic significance of epidermal growth factor receptor (EGFR) status in glioblastoma (GBM) patients. Accordingly, we attempted to assess the influence of EGFR expression on the survival of GBM patients receiving postoperative radiotherapy. MATERIALS AND METHODS: Thirty three GBM patients who had received surgery and postoperative radiotherapy at our institute, between March 1997 and February 2006, were included. The evaluation of EGFR expression with immunohistochemistry was available for 30 patients. Kaplan-Meier survival analysis and Cox regression were used for statistical analysis. RESULTS: EGFR was expressed in 23 patients (76.7%), and not expressed in seven (23.3%). Survival in EGFR expressing GBM patients was significantly less than that in non-expressing patients (median survival: 12.5 versus 17.5 months, p=0.013). Patients who received more than 60 Gy showed improved survival over those who received up to 60 Gy (median survival: 17.0 versus 9.0 months, p=0.000). Negative EGFR expression and a higher radiation dose were significantly correlated with improved survival on multivariate analysis. Survival rates showed no differences according to age, sex, and surgical extent. CONCLUSION: The expression of EGFR demonstrated a significantly deleterious effect on the survival of GBM patients. Therefore, approaches targeting EGFR should be considered in potential treatment methods for GBM patients, in addition to current management strategies.
